Circulating RNA as a tumor marker: Detection of 5T4 mRNA in breast and lung cancer patient serum

Michael S. Kopreski, Floyd A. Benko, Christopher Gocke

Research output: Contribution to journalArticle

Abstract

Cancer is commonly associated with the inappropriate mRNA expression of nonmutated genes. Recently, several tumor-associated RNA species, including tyrosinase mRNA and telomerase RNA, have been demonstrated in plasma and serum. The presence of tumor RNA in plasma and serum affords the opportunity to diagnose or stratify patients with cancer when tissue is not readily available. To exemplify the potential for pharmacogenomic and phenotypic stratification of the cancer patient, we evaluated serum for 5T4 mRNA. 5T4 is a trophoblast glycoprotein frequently overexpressed in epithelial malignancies that provides a potential target for cancer therapeutics. Serum was collected from 19 patients with advanced breast cancer (5 patients) or non-small-cell lung cancer (14 patients), and from 25 normal control volunteers having amplifiable RNA. RNA extracted from the serum was RT-PCR amplified using heminested, two-stage reactions, with products detected by gel electrophoresis. 5T4 mRNA was reproducibly detected in 8/19 (42%) cancer patient sera, including 2/5 breast cancer patient sera and 6/14 lung cancer patient sera, but in only 3/25 (12%) normal control sera (p = 0.035). The potential for circulating mRNA to identify patients who might benefit from a 5T4-directed therapy offers an example of the utility of circulating RNA as a tumor marker.

Original languageEnglish (US)
Pages (from-to)172-178
Number of pages7
JournalAnnals of the New York Academy of Sciences
Volume945
StatePublished - 2001
Externally publishedYes

Fingerprint

Tumor Biomarkers
Lung Neoplasms
RNA
Breast Neoplasms
Messenger RNA
Serum
Neoplasms
Tumors
Plasmas
Monophenol Monooxygenase
Electrophoresis
Glycoproteins
Genes
Gels
Cells
Lung Cancer
Cancer Patients
Breast Cancer
Tissue
Pharmacogenetics

Keywords

  • 5T4
  • Breast cancer
  • Lung cancer
  • Pharmacogenomic
  • Plasma
  • RNA
  • Serum

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Circulating RNA as a tumor marker : Detection of 5T4 mRNA in breast and lung cancer patient serum. / Kopreski, Michael S.; Benko, Floyd A.; Gocke, Christopher.

In: Annals of the New York Academy of Sciences, Vol. 945, 2001, p. 172-178.

Research output: Contribution to journalArticle

@article{31d60fb4f0b34113a8c0e0e60f5f8d7b,
title = "Circulating RNA as a tumor marker: Detection of 5T4 mRNA in breast and lung cancer patient serum",
abstract = "Cancer is commonly associated with the inappropriate mRNA expression of nonmutated genes. Recently, several tumor-associated RNA species, including tyrosinase mRNA and telomerase RNA, have been demonstrated in plasma and serum. The presence of tumor RNA in plasma and serum affords the opportunity to diagnose or stratify patients with cancer when tissue is not readily available. To exemplify the potential for pharmacogenomic and phenotypic stratification of the cancer patient, we evaluated serum for 5T4 mRNA. 5T4 is a trophoblast glycoprotein frequently overexpressed in epithelial malignancies that provides a potential target for cancer therapeutics. Serum was collected from 19 patients with advanced breast cancer (5 patients) or non-small-cell lung cancer (14 patients), and from 25 normal control volunteers having amplifiable RNA. RNA extracted from the serum was RT-PCR amplified using heminested, two-stage reactions, with products detected by gel electrophoresis. 5T4 mRNA was reproducibly detected in 8/19 (42{\%}) cancer patient sera, including 2/5 breast cancer patient sera and 6/14 lung cancer patient sera, but in only 3/25 (12{\%}) normal control sera (p = 0.035). The potential for circulating mRNA to identify patients who might benefit from a 5T4-directed therapy offers an example of the utility of circulating RNA as a tumor marker.",
keywords = "5T4, Breast cancer, Lung cancer, Pharmacogenomic, Plasma, RNA, Serum",
author = "Kopreski, {Michael S.} and Benko, {Floyd A.} and Christopher Gocke",
year = "2001",
language = "English (US)",
volume = "945",
pages = "172--178",
journal = "Annals of the New York Academy of Sciences",
issn = "0077-8923",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Circulating RNA as a tumor marker

T2 - Detection of 5T4 mRNA in breast and lung cancer patient serum

AU - Kopreski, Michael S.

AU - Benko, Floyd A.

AU - Gocke, Christopher

PY - 2001

Y1 - 2001

N2 - Cancer is commonly associated with the inappropriate mRNA expression of nonmutated genes. Recently, several tumor-associated RNA species, including tyrosinase mRNA and telomerase RNA, have been demonstrated in plasma and serum. The presence of tumor RNA in plasma and serum affords the opportunity to diagnose or stratify patients with cancer when tissue is not readily available. To exemplify the potential for pharmacogenomic and phenotypic stratification of the cancer patient, we evaluated serum for 5T4 mRNA. 5T4 is a trophoblast glycoprotein frequently overexpressed in epithelial malignancies that provides a potential target for cancer therapeutics. Serum was collected from 19 patients with advanced breast cancer (5 patients) or non-small-cell lung cancer (14 patients), and from 25 normal control volunteers having amplifiable RNA. RNA extracted from the serum was RT-PCR amplified using heminested, two-stage reactions, with products detected by gel electrophoresis. 5T4 mRNA was reproducibly detected in 8/19 (42%) cancer patient sera, including 2/5 breast cancer patient sera and 6/14 lung cancer patient sera, but in only 3/25 (12%) normal control sera (p = 0.035). The potential for circulating mRNA to identify patients who might benefit from a 5T4-directed therapy offers an example of the utility of circulating RNA as a tumor marker.

AB - Cancer is commonly associated with the inappropriate mRNA expression of nonmutated genes. Recently, several tumor-associated RNA species, including tyrosinase mRNA and telomerase RNA, have been demonstrated in plasma and serum. The presence of tumor RNA in plasma and serum affords the opportunity to diagnose or stratify patients with cancer when tissue is not readily available. To exemplify the potential for pharmacogenomic and phenotypic stratification of the cancer patient, we evaluated serum for 5T4 mRNA. 5T4 is a trophoblast glycoprotein frequently overexpressed in epithelial malignancies that provides a potential target for cancer therapeutics. Serum was collected from 19 patients with advanced breast cancer (5 patients) or non-small-cell lung cancer (14 patients), and from 25 normal control volunteers having amplifiable RNA. RNA extracted from the serum was RT-PCR amplified using heminested, two-stage reactions, with products detected by gel electrophoresis. 5T4 mRNA was reproducibly detected in 8/19 (42%) cancer patient sera, including 2/5 breast cancer patient sera and 6/14 lung cancer patient sera, but in only 3/25 (12%) normal control sera (p = 0.035). The potential for circulating mRNA to identify patients who might benefit from a 5T4-directed therapy offers an example of the utility of circulating RNA as a tumor marker.

KW - 5T4

KW - Breast cancer

KW - Lung cancer

KW - Pharmacogenomic

KW - Plasma

KW - RNA

KW - Serum

UR - http://www.scopus.com/inward/record.url?scp=0034750642&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034750642&partnerID=8YFLogxK

M3 - Article

C2 - 11708475

AN - SCOPUS:0034750642

VL - 945

SP - 172

EP - 178

JO - Annals of the New York Academy of Sciences

JF - Annals of the New York Academy of Sciences

SN - 0077-8923

ER -